MA38397A1 - Agglomérats inhalables de particules de support poreuses et médicament micronisé - Google Patents

Agglomérats inhalables de particules de support poreuses et médicament micronisé

Info

Publication number
MA38397A1
MA38397A1 MA38397A MA38397A MA38397A1 MA 38397 A1 MA38397 A1 MA 38397A1 MA 38397 A MA38397 A MA 38397A MA 38397 A MA38397 A MA 38397A MA 38397 A1 MA38397 A1 MA 38397A1
Authority
MA
Morocco
Prior art keywords
inhalable
agglomerates
porous carrier
carrier particles
particles
Prior art date
Application number
MA38397A
Other languages
English (en)
Inventor
Michael Hartman
Thomas Tarara
Patrick Teung
Jeffry Weers
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA38397A1 publication Critical patent/MA38397A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une composition pharmaceutique destinée à être administrée par voie pulmonaire qui se présente sous la forme de poudre sèche contenant des particules de support poreuses et des particules de principe actif. Les particules de support poreuses et les particules de principe actif forment un mélange ordonné d'agglomérats inhalables utiles pour traiter des maladies pulmonaires. Les particules de principe actif peuvent comprendre un, deux, trois ingrédients actifs ou plus. L'invention concerne également un procédé de séchage par pulvérisation destiné à la préparation des agglomérats inhalables.
MA38397A 2013-03-14 2014-03-13 Agglomérats inhalables de particules de support poreuses et médicament micronisé MA38397A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361784842P 2013-03-14 2013-03-14
PCT/IB2014/059739 WO2014141135A1 (fr) 2013-03-14 2014-03-13 Agglomérats inhalables de particules de support poreuses et médicament micronisé

Publications (1)

Publication Number Publication Date
MA38397A1 true MA38397A1 (fr) 2018-01-31

Family

ID=50478894

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38397A MA38397A1 (fr) 2013-03-14 2014-03-13 Agglomérats inhalables de particules de support poreuses et médicament micronisé

Country Status (22)

Country Link
US (2) US9452139B2 (fr)
EP (1) EP2968570A1 (fr)
JP (1) JP6374414B2 (fr)
KR (1) KR20150129716A (fr)
CN (1) CN105188757B (fr)
AU (2) AU2014229265A1 (fr)
BR (1) BR112015021814A2 (fr)
CA (1) CA2905615A1 (fr)
CL (1) CL2015002632A1 (fr)
EA (1) EA201591729A1 (fr)
GT (1) GT201500295A (fr)
HK (1) HK1212616A1 (fr)
IL (1) IL240963A (fr)
MA (1) MA38397A1 (fr)
MX (1) MX2015012814A (fr)
PE (1) PE20151655A1 (fr)
PH (1) PH12015501882A1 (fr)
SA (1) SA515361055B1 (fr)
SG (1) SG11201506397QA (fr)
TN (1) TN2015000395A1 (fr)
WO (1) WO2014141135A1 (fr)
ZA (1) ZA201505768B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007079139A2 (fr) 2005-12-28 2007-07-12 Vertex Pharmaceuticals, Inc. Formes solides de n-[2,4-bis(1,1-diméthyléthyl)-5-hydroxyphényl]-1,4-dihydro-4-oxoquinoléine-3-carboxamide
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
ES2608474T3 (es) 2010-04-22 2017-04-11 Vertex Pharmaceuticals Incorporated Proceso de producción de compuestos indol cycloalkylcarboxamido
US9682038B2 (en) * 2013-01-31 2017-06-20 Prosonix Limited Pharmaceutical compositions comprising multi-component crystalline particles suitable for use in inhalation therapy
US9452139B2 (en) * 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
MX2016012641A (es) * 2014-03-27 2016-12-14 Novartis Ag Dispersiones solidas secas en aceite en agua por aspersion para inhalacion de ingredientes farmaceuticos activos.
ES2885181T3 (es) 2014-04-15 2021-12-13 Vertex Pharma Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quística
KR20170063954A (ko) 2014-10-07 2017-06-08 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정
WO2016142708A2 (fr) * 2015-03-10 2016-09-15 Cipla Limited Composition pharmaceutique
US10423736B2 (en) * 2015-08-28 2019-09-24 University Of British Columbia Methods and systems for simulating hydrodynamics in gas-solid fluidized beds
EP3335699A1 (fr) 2016-12-15 2018-06-20 H e x a l Aktiengesellschaft Formulation de sélexipag dans un système liquisolide
CN106943350A (zh) * 2017-03-14 2017-07-14 上海现代药物制剂工程研究中心有限公司 含毒蕈碱受体拮抗剂和β2受体激动剂的气雾剂及制备方法
WO2019060595A1 (fr) * 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. Médicament inhalable en poudre sèche comprenant du glycopyrronium
US20200324064A1 (en) * 2019-04-10 2020-10-15 Cai Gu Huang Inhalation Device for Administering Powdered Pharmaceutical Composition
US20200375945A1 (en) * 2019-06-03 2020-12-03 Cai Gu Huang Inhalable formulation of a solution containing indacaterol maleate and glycopyrronium bromide
CN112137957B (zh) * 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
US20220322724A1 (en) * 2019-08-15 2022-10-13 Abbott Laboratories Nutritional powder manufacturing process using micronization, and powder composition
CA3175211A1 (fr) * 2020-04-13 2021-10-21 Matthias Emanuel LIECHTI Identification de dose de lsd
CN114344285B (zh) * 2020-10-14 2023-11-14 江苏恒瑞医药股份有限公司 改良的可吸入团聚物
WO2022122012A1 (fr) * 2020-12-11 2022-06-16 江苏恒瑞医药股份有限公司 Composition pharmaceutique pour administration pulmonaire
CN113318097A (zh) * 2021-04-29 2021-08-31 珠海瑞思普利医药科技有限公司 一种抗特发性肺纤维化的粉雾剂及制备方法
EP4329759A4 (fr) 2021-04-30 2025-07-16 Mind Medicine Inc Formes cristallines de sels de lsd
JP7846211B2 (ja) 2021-08-19 2026-04-14 デフィニウム セラピューティクス ユーエス， インコーポレイテッド 治療適用のためのｄ－リゼルグ酸ジエチルアミドの即時放出製剤
CN116785246A (zh) * 2022-03-17 2023-09-22 上海惠永药物研究有限公司 一种药物微球及含其的气雾剂
CN116785239A (zh) * 2022-03-17 2023-09-22 上海惠永药物研究有限公司 喷雾冷冻干燥制备微球的方法
CN117357485B (zh) * 2023-11-01 2024-09-24 山东京卫制药有限公司 一种改良的可吸入的载体颗粒及应用
WO2025256638A1 (fr) * 2024-06-14 2025-12-18 上海济昀生物科技有限公司 Composition d'aérosol à triple inhalation suspendue et son procédé de préparation

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
IT1016489B (it) 1974-03-18 1977-05-30 Isf Spa Inalatore
CY1359A (en) 1981-02-02 1987-08-07 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
SE448277B (sv) 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
SG43834A1 (en) 1991-06-26 1997-11-14 Schering Corp Inhalation device for powdered medicaments
DK0674533T3 (da) 1992-12-18 1999-09-27 Schering Corp Inhalator for medikamenter i pulverform
US6794357B1 (en) * 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
NZ293163A (en) 1994-09-21 1998-09-24 Inhale Therapeutic Syst Inhalation medicament disperser, aerosol from high pressure gas entrainment of fluidised powder drawn from receptacle feed tube
EP0938907B1 (fr) 1996-01-03 2001-12-05 Glaxo Group Limited Inhalateur
SK287878B6 (sk) 1996-02-21 2012-02-03 Schering Corporation Powdered medication inhaler
CN100391942C (zh) 1996-11-11 2008-06-04 索佛特克两合公司 对映异构纯的碱性芳基-环烷基-羟基羧酸酯,其制备方法及其在药品中的应用
US6613795B2 (en) 1996-11-11 2003-09-02 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
US6010935A (en) 1997-08-21 2000-01-04 Micron Technology, Inc. Self aligned contacts
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
UA73924C2 (en) 1998-10-09 2005-10-17 Nektar Therapeutics Device for delivering active agent formulation to lungs of human patient
PL200941B1 (pl) 1998-11-13 2009-02-27 Jagotec Ag Suchy proszkowy preparat inhalacyjny
US20070212422A1 (en) 1999-11-10 2007-09-13 Manfred Keller Dry powder for inhalation
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
MXPA01012246A (es) 1999-05-28 2002-08-12 Inhale Therapeutic Syst Aparato y metodo para distribuir una cantidad medida de medicamento en aerosol.
US20010029947A1 (en) 1999-12-17 2001-10-18 Steve Paboojian Receptacles to facilitate the extraction of powders
US7069929B2 (en) 2000-02-01 2006-07-04 Quadrant Technologies Limited Dry powder inhaler
PT1280520E (pt) 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
EP1569626A1 (fr) 2002-12-13 2005-09-07 Adagit Particules pharmaceutiques poreuses
JP4943838B2 (ja) 2003-04-09 2012-05-30 ネクター セラピューティクス 空気入口シールドを備えたエアゾール化装置
GB0317374D0 (en) 2003-07-24 2003-08-27 Glaxo Group Ltd Medicament dispenser
GB2407042B (en) 2003-10-17 2007-10-24 Vectura Ltd Inhaler
WO2005081833A2 (fr) 2004-02-24 2005-09-09 Microdose Technologies, Inc. Procede et appareil d'administration de medicaments a jet synthetique
GB0410712D0 (en) 2004-05-13 2004-06-16 Novartis Ag Organic compounds
GB0413960D0 (en) 2004-06-22 2004-07-28 Novartis Ag Organic compounds
ITMI20051999A1 (it) 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
PT2044025E (pt) 2006-06-30 2012-12-17 Novartis Ag Derivados de quinolinona e suas composições farmacêuticas
EP2077882A2 (fr) 2006-10-25 2009-07-15 Nektar Therapeutics Appareil de dispersion de poudre, procédé de fabrication et d'utilisation de l'appareil et composant pouvant être utilisé sur l'appareil et d'autres dispositifs
MX2010012452A (es) 2008-05-15 2011-03-15 Novartis Ag Star Suministro pulmonar de una fluoro-quinolona.
ES2617680T3 (es) 2009-04-09 2017-06-19 Novartis Ag Proceso para la preparación de sales de pirrolidinio
US8815258B2 (en) * 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
CN104257610A (zh) 2010-04-01 2015-01-07 奇斯药制品公司 用于制备可吸入干粉所用的载体颗粒的方法
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
US9452139B2 (en) * 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug

Also Published As

Publication number Publication date
US9744178B2 (en) 2017-08-29
IL240963A (en) 2017-05-29
KR20150129716A (ko) 2015-11-20
US9452139B2 (en) 2016-09-27
HK1212616A1 (zh) 2016-06-17
PH12015501882A1 (en) 2015-12-07
GT201500295A (es) 2017-09-28
AU2017203258B2 (en) 2019-06-20
BR112015021814A2 (pt) 2017-07-18
JP2016512494A (ja) 2016-04-28
EA201591729A1 (ru) 2016-05-31
AU2017203258A1 (en) 2017-06-08
ZA201505768B (en) 2017-03-29
US20140302147A1 (en) 2014-10-09
IL240963A0 (en) 2015-11-30
WO2014141135A1 (fr) 2014-09-18
SA515361055B1 (ar) 2016-11-13
CA2905615A1 (fr) 2014-09-18
CL2015002632A1 (es) 2016-03-28
MX2015012814A (es) 2016-02-03
SG11201506397QA (en) 2015-09-29
PE20151655A1 (es) 2015-11-26
US20160354388A1 (en) 2016-12-08
JP6374414B2 (ja) 2018-08-15
EP2968570A1 (fr) 2016-01-20
TN2015000395A1 (en) 2017-01-03
CN105188757B (zh) 2019-04-30
CN105188757A (zh) 2015-12-23
AU2014229265A1 (en) 2015-09-03

Similar Documents

Publication Publication Date Title
MA38397A1 (fr) Agglomérats inhalables de particules de support poreuses et médicament micronisé
MA34449B1 (fr) Formulation de poudre seche comprenant un inhibiteur de phosphodiesterase
PH12021550166A1 (en) Nlrp3 inflammasome inhibitors
DE60129573D1 (de) Verfahren zur sprühtrocknung von zusammensetzungen enthaltend fenofibrat
UA107499C2 (uk) Склад сухого порошку, який містить антимускариновий засіб
BRPI0411165A (pt) composição farmacêutica, forma de unidade de dosagem e métodos para preparar seu uso
MX344787B (es) Composiciones que contienen berberina o analogos de la misma para tratar rosacea o trastornos de la piel relacionados con enrojecimiento de la cara.
ATE487720T1 (de) 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
BRPI0508170A (pt) formulações farmacêuticas para inaladores de pó seco, que compreendem um ingrediente ativo de potência de baixa dosagem
BR112015020443A2 (pt) desamorfização de formulações secadas por atomização via mistura por atomização
EA201700182A1 (ru) Состав для повышения стабильности лекарственного препарата, содержащий по меньшей мере один сухой порошок, полученный распылительной сушкой
MA43876B1 (fr) Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale
EA201401309A1 (ru) Фармацевтическая композиция для ингаляции, содержащая аклидиний, и её применение
EA200500387A1 (ru) Композиции для ингаляции с высоким содержанием лекарственных веществ
EA202092922A1 (ru) Фармацевтический состав с улучшенной растворимостью и биологической доступностью
EA201170583A1 (ru) Новая композиция для лечения эссенциальной тромбоцитемии
EA026665B1 (ru) Твердые формы препаратов иматиниба, ресуспензируемые непосредственно перед применением
EA200801614A1 (ru) Фармацевтическая композиция, содержащая монтелукаст
EA200801447A1 (ru) Фармацевтическая композиция
EA201792159A1 (ru) Способ получения сухих порошкообразных смесей
EA202091127A1 (ru) Фармацевтические композиции, включающие сафинамид
MA35698B1 (fr) Nouvelle composition du 3,4-diaminopyridin pour le traitement de la fatigabilité musculaire associée à des troubles neurovégétatifs.
EA201171014A1 (ru) Средство противовирусной и иммуностимулирующей активности, способ получения средства противовирусной и иммуностимулирующей активности, способ профилактики и лечения инфекционных болезней
EA200101157A1 (ru) 14β-H-СТЕРОЛЫ, СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И ПРИМЕНЕНИЕ ЭТИХ ПРОИЗВОДНЫХ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ, РЕГУЛИРУЮЩИХ МЕЙОЗ